← Back to Search

[89Zr]Panitumumab PET-MRI for Colon Cancer (Panitumumab Trial)

Phase 1 & 2
Waitlist Available
Led By Suzanne Lapi, PhD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Panitumumab Trial Summary

This trial will use PET imaging with [89Zr]Panitumumab to assess if and how much EGFR expression is present in colon cancer patients' lymph nodes to help determine if they are involved in the cancer.

Eligible Conditions
  • Colon Cancer

Panitumumab Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Image Quality

Panitumumab Trial Design

1Treatment groups
Experimental Treatment
Group I: [89Zr]Panitumumab-PET/MRI patientsExperimental Treatment1 Intervention
All study patients will receive [89Zr]Panitumumab-PET/MRI imaging.

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,590 Previous Clinical Trials
2,281,482 Total Patients Enrolled
Suzanne Lapi, PhDPrincipal InvestigatorUniversity of Alabama at Birmingham
1 Previous Clinical Trials
14 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~0 spots leftby Jan 2025